Lion's Mane Dosage: What the Trials Actually Used
Lion's mane dosage: the trials used 3 g/day of plain fruiting-body powder, not extracts. Dose-by-goal guide, the NGF claim stated precisely, plus safety.
Lion's mane (Hericium erinaceus) is the mushroom of the moment for memory and focus — and the dosing conversation around it is a mess. The single best human trial used 3 grams per day of plain dried fruiting-body powder, while most commercial products sell dual-extracted concentrates at 500 mg–1 g per day. Those are different products, and the trial result does not automatically transfer.
This guide gives you what was actually studied, what our remedy page recommends, and where the famous "NGF" claim really stands.
Evidence-Based Guide | Brain Health
About Lion's Mane
Lion's mane is an edible mushroom (also a culinary delicacy) used in traditional Chinese medicine. Its bioactive compounds of interest are hericenones (found in the fruiting body) and erinacines (found in the mycelium), studied for their relationship to nerve growth factor (NGF) synthesis — a protein involved in the maintenance, growth, and survival of nerve cells (Lai et al., Int J Med Mushrooms 2013;15(6):539–554, preclinical review, PMID 24266378).
Human clinical evidence is thin: a handful of small trials (n=30–77), mostly short — Mori 2009 (n=30, 16 wk, cognition), Nagano 2010 (n=30, 4 wk, mood), Saitsu 2019 (n=31, 12 wk, 0.8 g/day cookies, cognition/MMSE), Vigna 2019 (n=77, 8 wk, mood/sleep), and Li 2020 (erinacine-A-enriched mycelia pilot, 49 wk, mild cognitive decline). Everything else — the week-by-week timelines, the "2–4 weeks to feel it" claims — is user anecdote, not trial data.
The Honest Evidence Picture
- *Mori et al. (2009, Phytotherapy Research):* 30 adults with mild cognitive impairment randomized to 3 g/day of dried lion's mane fruiting-body powder (four 250 mg tablets — 96% Yamabushitake dry powder — three times daily) or placebo for 16 weeks. HDS-R-based cognitive scores were significantly higher vs placebo at weeks 8, 12, and 16 — then fell significantly by 4 weeks after supplementation stopped (Mori K et al., Phytother Res 2009;23(3):367–372, PMID 18844328).
- *Nagano et al. (2010, Biomedical Research):* 30 menopausal women randomized to cookies containing lion's mane powder (500 mg powdered fruiting body per cookie × 4 cookies/day = 2 g/day, Aso Biotech Inc powder) or placebo for 4 weeks. Depression (CES-D) and 'indefinite complaints' (ICI) improved vs BASELINE — but vs placebo, only two ICI symptom terms ('insensitive' and 'palpitation') were significantly lower; 'concentration,' 'irritating,' and 'anxious' only trended lower (Biomed Res (Tokyo) 2010;31(4):231–237, PMID 20834180).
- Everything else is preclinical. NGF stimulation, neurite outgrowth, neuroprotection against various insults — demonstrated in cell culture and animal models, not in humans. No human trial (Mori 2009, Nagano 2010, Saitsu 2019, Vigna 2019, Li 2020) has measured NGF in people; they measured cognitive/mood scores and (Vigna 2019) pro-BDNF/BDNF. NGF-synthesis stimulation is documented only in vitro (e.g., Kawagishi 1991/1994) and in animals (e.g., Shimbo 2005). Note: Mori 2008 measured NGF-inducing activity in human astrocytoma cells — in vitro, not in humans.
Five small trials is a suggestive evidence base, not a proven one. The Mori trial is genuinely encouraging — cognitive scores moved and then fell back when the mushroom stopped, which is the pattern you'd expect from a real effect — but it needs replication at larger scale before anyone calls lion's mane "clinically proven" for anything.
The NGF Claim, Precisely Stated
You'll see lion's mane marketed as "clinically proven to stimulate NGF production." Here's the precise version:
- Preclinical (in vitro and animal): hericenones and erinacines stimulate NGF synthesis in cultured cells and show neurotrophic effects in animals. This is real, published science — the primary papers are Kawagishi et al., Tetrahedron Lett. 1991;32:4561–4564 (hericenones C, D, E — NGF-synthesis stimulators from the fruiting body) and Kawagishi et al., Tetrahedron Lett. 1994;35:1569–1572 (erinacines A, B, C — strong NGF-synthesis stimulators from the mycelia), both in-vitro assays. (Note: Phan et al. 2015 is a review, not a primary erinacine study.)
- Human: no published study has measured NGF levels in people taking lion's mane. The human trials measured cognitive test scores, not NGF.
So "stimulates NGF" is a preclinical finding, and "clinically proven to stimulate NGF" conflates two different levels of evidence. Our site's remedy page carries the "only mushroom clinically proven to stimulate NGF production" line — but no human study has measured NGF after lion's mane, so no mushroom can be 'clinically proven to stimulate NGF' on this basis. Replace with preclinical framing ('studied in lab and animal models for compounds that stimulate NGF synthesis'); the 'only mushroom' superlative is itself unverified. Flagged to the owner as a remedy-page fix (same class as the shankhpushpi/giloy page fixes). Similarly, the site page's "Improves memory 30%" figure is untraceable to any published trial — Mori 2009 reported improved cognitive test scores, never a percentage. Drop the number entirely; if a benefit line is kept, use 'improved cognitive test scores in one small 16-week trial.' Flagged to the owner as a remedy-page fix.
Dose by Goal
| Goal | Form | Dose | Duration / notes |
|---|---|---|---|
| Cognitive support / memory (trial-anchored) | Dried fruiting-body powder (not extract) | 3 g/day | Mori et al. 2009: 3 g/day for 16 weeks in mild cognitive impairment (n=30); scores improved at weeks 8/12/16 vs placebo, declined 4 weeks after stopping. The best-studied dose for cognition — though Saitsu 2019 found cognitive improvement with 0.8 g/day cookies (n=31, 12 wk), and Nagano 2010 (2 g/day) and Vigna 2019 (1.5 g/day) have mood/sleep efficacy data |
| Everyday cognitive / wellness (site guidance) | Dual-extracted powder | 500 mg–1 g/day in the morning | Our site's /remedies/lions-mane-mushroom page recommends morning use for cognitive benefits (wording confirmed live 2026-10-10). Note: this is a different product class than the trial's plain powder — the trial dose does not validate the extract dose |
| Mood / mild anxiety-depression (exploratory) | Fruiting-body powder in cookies | 2 g/day (500 mg per cookie × 4 cookies) | Nagano et al. 2010 (n=30 menopausal women, 4 weeks): CES-D and ICI improved vs baseline; only two ICI symptom terms beat placebo. Very small, very specific population — not generalizable |
| Culinary use | Fresh or dried mushroom as food | Per meal | Lion's mane is an edible mushroom; culinary doses are not trial doses and carry no efficacy implication |
Forms: Powder vs Dual Extract vs Mycelium
This is where most buyers go wrong, because the products are genuinely different things:
- Dried fruiting-body powder: What Mori 2009 used (3 g/day). The whole mushroom, dried and powdered. Contains hericenones plus the full matrix of the fruiting body.
- Dual extract (hot water + alcohol): Concentrates both water-soluble beta-glucans and alcohol-soluble compounds (hericenones/erinacines). More "potent" per gram, but no human COGNITION trial used a dual extract (Vigna 2019's product did include a water/ethanol-extracted fruiting-body portion alongside mycelium powder) — so the 3 g/day trial figure doesn't apply to it, and there's no trial-derived extract dose.
- Mycelium / "myceliated grain": Many cheap products are mycelium grown on grain (oats/rice) — the final product can be mostly starchy grain filler with undisclosed beta-glucan content. Erinacines are a mycelium compound, which marketers use to justify these products, but the cognition trials (Mori 2009, Nagano 2010, Saitsu 2019) used fruiting-body material — Vigna 2019 used 80% mycelium powder + 20% fruiting-body extract and Li 2020 used erinacine-A-enriched mycelia.
- Tinctures and gummies: Convenience formats; no trial data; dosing is label-dependent.
Bottom line: if you want the dose with human data behind it, it's 3 g/day of fruiting-body powder. Everything else is extrapolation.
Safety, Side Effects & Interactions
The safety record is reassuring but thin. No significant organ toxicity has been documented in the published studies, and lion's mane has centuries of culinary use. But long-term human safety data at supplement doses is limited — two small short trials plus traditional food use is not the same as a large safety database.
- Do not combine with blood thinners without clinician supervision — our site's page flags possible increased bleeding risk. Mori et al. 2010 (Phytomedicine; PMID 20637576) showed hericenone B selectively inhibited collagen-induced platelet aggregation in rabbit and human platelets in vitro. Theoretical-but-plausible; clinician supervision is a reasonable caution.
- Do not expect "30% memory improvement" — untraceable to any trial; the Mori trial reported score improvements, not a percentage.
- Mushroom allergy: rare allergic reactions are documented — two anaphylaxis cases (food and supplement), a 63-year-old male who developed acute respiratory failure with lung lymphocytosis after 4 months of daily extract (Sabaratnam, J Restor Med 2017), occupational chronic dermatitis with a positive open application test to H. erinaceus fruiting body, and NIH LiverTox's note of 'at least one example of an acute hypersensitivity reaction to oral lion's mane.' Avoid if you're allergic to mushrooms.
- Very high doses: itchy skin/skin rash has been reported anecdotally at higher doses, and skin rash appeared in one small clinical study (Li 2020 pilot); MSKCC lists 'skin rash' as a reported side effect. The 'via increased NGF activity' mechanism is unsourced speculation — dropped.
- Blood sugar: a possible blood-sugar-lowering interplay with diabetes medications is theoretical only — the sole evidence is animal (Liang et al., BMC Complement Altern Med 2013;13:253, PMID 24090482: aqueous extract 100/200 mg/kg for 28 days lowered serum glucose and raised insulin in STZ diabetic rats; no human interaction data).
- Pregnancy and breastfeeding: safety not studied — no published human pregnancy/breastfeeding safety data and no authority guidance found (Herbal Reality monograph: 'There is no existing research into its safe use during pregnancy or when breastfeeding'). Avoid as a supplement (culinary use is a separate question).
What to Look For on the Label
- "100% fruiting body" — and specifically whether it's powder or extract; the human trial used dried fruiting-body powder, not an extract.
- Stated beta-glucan content (not just "polysaccharides," which includes starch from grain fillers).
- Dual extraction stated explicitly if buying an extract (hot water + alcohol) — single-method extracts miss either the beta-glucans or the triterpenoid fraction.
- Avoid "myceliated grain" products with undisclosed starch content — this is standard quality guidance in the mushroom-supplement space (Real Mushrooms and Nootropics Depot both explicitly contrast fruiting-body products against mycelium-on-grain fillers; independent lab analyses found some commercial products' compound profiles resemble their grain substrate).
- Third-party testing for heavy metals and identity; avoid products making NGF claims as if human-measured.
- No mega-dose logic: the trial used 3 g of powder; 3 g of a 10:1 extract is not the same thing.
❓ Frequently Asked Questions
📢 Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any new supplement. Sources are linked for verification.
📚 Clinical Research & Sources
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res (2009);23(3):367–372 — four 250 mg tablets (96% Yamabushitake dry powder) three times daily = 3 g/day; HDS-R-based cognitive scores significantly higher vs placebo at weeks 8/12/16, fell significantly 4 weeks post-treatment; no adverse lab effects (PMID 18844328; DOI 10.1002/ptr.2634) ()[Source ↗]
- Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res (Tokyo) (2010);31(4):231–237 — n=30, 2 g/day powder in cookies (500 mg per cookie × 4/day), 4 weeks; CES-D and ICI improved vs baseline, only two ICI terms significant vs placebo (PMID 20834180; DOI 10.2220/biomedres.31.231) ()[Source ↗]
- Lai PL, Naidu M, Sabaratnam V, Wong KH, David RP, Kuppusamy UR, Abdullah N, Malek SN. Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia. Int J Med Mushrooms (2013);15(6):539–554 — preclinical (in vitro/animal) review of NGF-related neurotrophic properties (PMID 24266378; DOI 10.1615/intjmedmushr.v15.i6.30) ()[Source ↗]
- Kawagishi H et al. Hericenones C, D and E — stimulators of NGF synthesis from the fruiting body of Hericium erinaceus (in vitro). Tetrahedron Lett (1991);32:4561–4564; and Kawagishi H et al. Erinacines A, B and C — strong stimulators of NGF synthesis from the mycelia (in vitro). Tetrahedron Lett (1994);35:1569–1572
- organicalt.com/remedies/lions-mane-mushroom — the site's own remedy page; source of the 500 mg–1 g/day morning guidance; the "only mushroom clinically proven to stimulate NGF" line and the "Improves memory 30%" figure are both flagged as overstated/untraceable (wording confirmed live 2026-10-10) ()[Source ↗]
- MSKCC About Herbs — Lion's Mane Mushroom monograph ()[Source ↗]
- NIH LiverTox — Lion's Mane (likelihood score E, unlikely cause of clinically apparent liver injury; no hepatotoxicity case reports) ()[Source ↗]
- Mori K et al. 2010 — hericenone B antiplatelet activity, collagen-induced platelet aggregation in rabbit and human platelets in vitro (PMID 20637576) ()[Source ↗]
- Liang B et al. 2013 — hypoglycemic effects of aqueous extract in STZ diabetic rats (PMID 24090482) ()[Source ↗]
- Vigna L et al. 2019 — 8-week lion's mane supplementation (80% mycelium + 20% fruiting-body extract) on mood and sleep in overweight/obesity ()[Source ↗]
- Li IC et al. 2020 — erinacine-A-enriched mycelia pilot, 49 weeks, mild cognitive decline ()[Source ↗]
Explore the Full Remedy Database
Browse 500+ organic alternatives for health, wellness, and natural living.
Browse All Remedies →